As a less expensive test to distinguish between LC and BLD in general practice clinics, the combination of four serum biomarkers (CYFR21, CEA, NSE, and SCC) seems more promising for the diagnosis of lung cancer and should be used in common practice. The gene discussed is CEACAM5; the disease is laryngotracheoesophageal cleft.